Literature DB >> 32167442

Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck.

Michael P Stevens1, Payal K Patel2, Priya Nori3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32167442      PMCID: PMC7137534          DOI: 10.1017/ice.2020.69

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   6.520


× No keyword cloud information.
To the Editor—To our knowledge, no formal recommendations exist for the inclusion of antimicrobial stewardship programs (ASPs) in disaster planning or emergency response preparedness efforts.[1] A PubMed search utilizing the search terms “antimicrobial stewardship” AND “disaster planning” was performed on March 4, 2020, and yielded no results. ASPs are now ubiquitous. They often include pharmacists and physicians with advanced infectious diseases training, and they are a valuable part of hospital safety and quality programs. In some hospitals, compartmentalization of stewardship and epidemiology functions have developed over time to meet distinct institutional needs. However, domains should coalesce for purposes of emergency preparedness. The current SARS-CoV-2/COVID-19 outbreak highlights numerous opportunities where ASPs can support emerging pathogen response and planning efforts. An informal Twitter poll was initiated on March 1, 2020, asking the infectious diseases and antimicrobial stewardship communities whether ASPs at their health systems had been involved in SARS-CoV-2/COVID-19 outbreak response or preparation. This yielded 254 responses: 30% noted direct involvement, 28% indicated indirect involvement, and 39% indicated no involvement in emergency response efforts or planning. Although formalized study is needed, real-time insights from the community provided valuable information. We identified multiple potential areas where ASPs can support emergency response efforts, and these are summarized in Figure 1.
Fig. 1.

Opportunities for antimicrobial stewardship programs to assist COVID-19 response preparation and planning efforts.

Opportunities for antimicrobial stewardship programs to assist COVID-19 response preparation and planning efforts. ASPs that are integrated with hospital infection prevention programs have an advantage in response efforts to emerging pathogens in that (1) they are likely to have pre-existing infection prevention skills and experience, (2) they are likely to be involved in response efforts early, and (3) they will have access to and influence with key stakeholders. Because ASPs and infection prevention programs share similar technology infrastructure, data, and metrics, program integration has many advantages.[2] Response efforts to novel respiratory viruses like SARS-CoV-2/COVID-19 represent an opportunity for programs to formally integrate, to develop cross-coverage capabilities, and to create shared leadership opportunities. ASPs can support SARS-CoV-2/COVID-19 response efforts in numerous ways within the context of their normal daily activities. A core component of antimicrobial stewardship includes postprescriptive review with feedback to providers.[3] In this way, an ASP skill set can theoretically assist with early identification of potential cases. This approach may be especially useful in situations in which the definition of a person under investigation is fluid because traditional epidemiologic efforts usually focus on identifying patients at the point of entry into health systems. ASPs often coordinate with microbiology laboratories for real-time interpretation and action involving upper respiratory PCR test results. They can support SARS-CoV-2/COVID-19 evaluation efforts in this fashion as well. Novel respiratory virus outbreaks associated with secondary bacterial pneumonias and acute respiratory distress syndrome (ARDS) provide an opportunity for ASPs to monitor compliance with guideline-concordant therapy; severe COVID-19 cases have been treated with broad-spectrum antibiotics.[4] Additionally, ASPs can help in the development of local treatment protocols involving repurposed antivirals; they can monitor and manage drug shortages due to supply chain interruptions[5]; and they can assist frontline providers with expanded access investigational new drug applications (eINDs) and local institutional review board procedures for investigational agents. ASPs are now mandated in the United States and are often multidisciplinary. The Joint Commission accreditation standard for ASPs includes, when available, an infectious diseases physician, pharmacist, infection preventionist, and other practitioners.[6] ASP physician and pharmacy leaders often have specialized infectious diseases training.[3] Leveraging these resources for planning and response efforts for emerging pathogens is critical and can strengthen and sustain collaborative relationships. We recommend that hospital epidemiology programs strongly consider integrating their ASP colleagues into disaster preparedness plans as well as identify a more formal role for stewards in their operations beyond the current COVID-19 outbreak.
  4 in total

Review 1.  The Role of the Hospital Epidemiologist in Antibiotic Stewardship.

Authors:  Salma Abbas; Michael P Stevens
Journal:  Med Clin North Am       Date:  2018-09       Impact factor: 5.456

2.  Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting.

Authors:  Sarah B Doernberg; Lilian M Abbo; Steven D Burdette; Neil O Fishman; Edward L Goodman; Gary R Kravitz; James E Leggett; Rebekah W Moehring; Jason G Newland; Philip A Robinson; Emily S Spivak; Pranita D Tamma; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2018-09-28       Impact factor: 9.079

3.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.

Authors:  Barnaby Edward Young; Sean Wei Xiang Ong; Shirin Kalimuddin; Jenny G Low; Seow Yen Tan; Jiashen Loh; Oon-Tek Ng; Kalisvar Marimuthu; Li Wei Ang; Tze Minn Mak; Sok Kiang Lau; Danielle E Anderson; Kian Sing Chan; Thean Yen Tan; Tong Yong Ng; Lin Cui; Zubaidah Said; Lalitha Kurupatham; Mark I-Cheng Chen; Monica Chan; Shawn Vasoo; Lin-Fa Wang; Boon Huan Tan; Raymond Tzer Pin Lin; Vernon Jian Ming Lee; Yee-Sin Leo; David Chien Lye
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

4.  Outbreak Response and Incident Management: SHEA Guidance and Resources for Healthcare Epidemiologists in United States Acute-Care Hospitals.

Authors:  David B Banach; B Lynn Johnston; Duha Al-Zubeidi; Allison H Bartlett; Susan Casey Bleasdale; Valerie M Deloney; Kyle B Enfield; Judith A Guzman-Cottrill; Christopher Lowe; Luis Ostrosky-Zeichner; Kyle J Popovich; Payal K Patel; Karen Ravin; Theresa Rowe; Erica S Shenoy; Roger Stienecker; Pritish K Tosh; Kavita K Trivedi
Journal:  Infect Control Hosp Epidemiol       Date:  2017-11-30       Impact factor: 3.254

  4 in total
  30 in total

1.  Pharmacist's Role and Pharmaceutical Care During the COVID-19 Pandemic.

Authors:  Pedro Amariles; Mónica Ledezma-Morales; Andrea Salazar-Ospina; Jaime Alejandro Hincapié-García
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Preparedness of pharmacists to respond to the emergency of the COVID-19 pandemic in Brazil: a comprehensive overview.

Authors:  Maria Auxiliadora Parreiras Martins; Amanda Fonseca de Medeiros; Claudmeire Dias Carneiro de Almeida; Adriano Max Moreira Reis
Journal:  Drugs Ther Perspect       Date:  2020-07-31

3.  Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID.

Authors:  Jorge Calderón-Parra; Antonio Muiño-Miguez; Alejandro D Bendala-Estrada; Antonio Ramos-Martínez; Elena Muñez-Rubio; Eduardo Fernández Carracedo; Javier Tejada Montes; Manuel Rubio-Rivas; Francisco Arnalich-Fernandez; Jose Luis Beato Pérez; Jose Miguel García Bruñén; Esther Del Corral Beamonte; Paula Maria Pesqueira Fontan; Maria Del Mar Carmona; Rosa Fernández-Madera Martínez; Andrés González García; Cristina Salazar Mosteiro; Carlota Tuñón de Almeida; Julio González Moraleja; Francesco Deodati; María Dolores Martín Escalante; María Luisa Asensio Tomás; Ricardo Gómez Huelgas; José Manuel Casas Rojo; Jesús Millán Núñez-Cortés
Journal:  PLoS One       Date:  2021-05-11       Impact factor: 3.240

4.  Guidance for the management of adult patients with coronavirus disease 2019.

Authors:  Jie-Ming Qu; Chen Wang; Bin Cao
Journal:  Chin Med J (Engl)       Date:  2020-07-05       Impact factor: 2.628

Review 5.  Global Antimicrobial Stewardship with a Focus on Low- and Middle-Income Countries.

Authors:  Jacob Pierce; Anucha Apisarnthanarak; Natalie Schellack; Wanda Cornistein; Amal Al Maani; Syamhanin Adnan; Michael P Stevens
Journal:  Int J Infect Dis       Date:  2020-06-04       Impact factor: 3.623

6.  Practitioners specialized in oral health and coronavirus disease 2019: Professional guidelines from the French society of stomatology, maxillofacial surgery and oral surgery, to form a common front against the infectious risk.

Authors: 
Journal:  J Stomatol Oral Maxillofac Surg       Date:  2020-04       Impact factor: 1.569

7.  Trends in Antibiotic Use in United States Hospitals During the Coronavirus Disease 2019 Pandemic.

Authors:  Ashley N Rose; James Baggs; Hannah Wolford; Melinda M Neuhauser; Arjun Srinivasan; Adi V Gundlapalli; Sujan Reddy; Lyudmyla Kompaniyets; Audrey F Pennington; Cheri Grigg; Sarah Kabbani
Journal:  Open Forum Infect Dis       Date:  2021-06-03       Impact factor: 3.835

8.  Practical implementation of COVID-19 patient flags into an antimicrobial stewardship program's prospective review.

Authors:  Ryan W Stevens; Lynn Estes; Christina Rivera
Journal:  Infect Control Hosp Epidemiol       Date:  2020-04-15       Impact factor: 3.254

9.  Impact of COVID-19 on traditional healthcare-associated infection prevention efforts.

Authors:  Michael P Stevens; Michelle Doll; Rachel Pryor; Emily Godbout; Kaila Cooper; Gonzalo Bearman
Journal:  Infect Control Hosp Epidemiol       Date:  2020-04-16       Impact factor: 3.254

10.  Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship.

Authors:  Kathrin Rothe; Susanne Feihl; Jochen Schneider; Fabian Wallnöfer; Milena Wurst; Marina Lukas; Matthias Treiber; Tobias Lahmer; Markus Heim; Michael Dommasch; Birgit Waschulzik; Alexander Zink; Christiane Querbach; Dirk H Busch; Roland M Schmid; Gerhard Schneider; Christoph D Spinner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-11-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.